Skip To Main Content
Teresa Cabaleiro on Muck Rack

Teresa Cabaleiro

As seen in: BMJ Open, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Teresa

Contact Teresa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and efficacy of personalised versus standard dosing of linezolid in patients with sepsis (SePkLin): a pragmatic, multicentre, randomised, controlled and superiority clinical trial protocol

|
By Enrique Bandín-Vilar, Ana Estany-Gestal, Teresa Cabaleiro, Eva Rial-Pensado
| BMJ Open Verified
Methods and analysis A pragmatic, multicentre, randomised, parallel, controlled and phase IV clinical trial, which aims to demonstrate the superiority of individualised dosing of PK/PD-based linezolid versus standard dosing. A 28-day follow-up will be carried out per patient recruited. The trial was designed following the Standard Protocol Items: Recommendations for Interventional Trials Statement (SPIRIT).
Open in Who Shared Issue with article?

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

|
By Francisco Abad-Santos, Dolores Ochoa Verified, Manuel Román Verified, Teresa Cabaleiro
| Biomed Central (BMC)
Research article Open Access Published: 25 July 2020 Dolores Ochoa1,2, Manuel Román1,2, Teresa Cabaleiro1,2, 1,3, Gina Mejía1,2 & ORCID: orcid.org/0000-0002-6519-88851,2,4 BMC Pharmacology and Toxicology volume 21, Article number: 54 (2020) Cite this article 527 Accesses 2 Altmetric Metrics details Abstract Background The pharmacokinetics of proton pump inhibitors (PPIs) may be affected by food intake.
Open in Who Shared Issue with article?

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis

|
By Rocío Prieto-Pérez, Mar Llamas-Velasco, Teresa Cabaleiro, Guillermo Solano-López
| Future Medicine Verified
Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis Aim/Materials & methods: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We evaluated 121 polymorphisms to study a possible association between these SNPs and the response to ustekinumab (PASI75 at 4 months; n = 69).
Open in Who Shared Issue with article?
See all 3 articles